# Molecular Insight Pharmaceuticals

Startup profile on Capital Atlas: https://capitalatlas.ai/startups/molecular-insight-pharmaceuticals

- Industry: Pharmaceuticals
- Headquarters: Cambridge, US
- Website: www.molecularinsight.com
- Total disclosed funding: $35M
- Latest round: Series C (Apr 21, 2005)
- Investors on record: 5

## About

Molecular Insight Pharmaceuticals engages in the development and commercialization of innovative diagnostic imaging and therapeutic agents to enhance patient care, particularly in the field of oncology.Molecular Insight Pharmaceuticals specializes in the development of novel radiopharmaceuticals for diagnosis and treatment in oncology. The company is headquartered in Cambridge, US. In February 2007, the company completed an IPO, pricing 5 million shares at USD 5 each, raising a total of USD 70 mn. The company has been involved in 9 deals since its inception.Molecular Insight Pharmaceuticals focuses on creating advanced diagnostic and therapeutic solutions for cancer care. Their key offerings include innovative radiopharmaceuticals designed for targeted imaging and treatment of various cancers. These products aim to enhance diagnostic accuracy and treatment efficacy for healthcare providers. Their services are accessible to a wide range of healthcare facilities and institutions, promoting better patient outcomes through precise medical interventions.In the most recent year, 2009, the company reported a revenue of USD 5.50 mn and an EBITDA of USD -45.34 mn, reflecting their operational financial status during that period.The company plans to leverage its recent funding from the 2007 IPO to expand its product line and enhance its research capabilities. They are focused on developing new radiopharmaceuticals aimed at improving cancer treatment efficacy, with releases anticipated in the next few years. Additionally, Molecular Insight Pharmaceuticals intends to explore expansion into international markets, particularly in Europe and Asia, by 2010, to increase access to their innovative solutions.

## Funding rounds

- Series C, Apr 21, 2005, $28M — Cerberus Capital Management, N47, Emigrant Capital, MedCap, Tudor Investment Corporation
- Series B, May 19, 2004, $7M — Cerberus Capital Management

## Investors

- Cerberus Capital Management (https://capitalatlas.ai/funds/cerberus-capital-management) — Series B, Series C
- N47 (https://capitalatlas.ai/funds/n47) — Series C
- Emigrant Capital (https://capitalatlas.ai/funds/emigrant-capital) — Series C
- MedCap (https://capitalatlas.ai/funds/medcap) — Series C
- Tudor Investment Corporation — Series C